CanSino Bio to Release New COVID-19 Vaccine in Indonesia

By Editorial Team 03/03/2023
COVID-19 vaccine vials
Summary

CanSino Biologics Inc (CanSino Bio) claims to have secured an emergency use of authorization (EUA) from the Food and Drug Monitoring Agency (BPOM) for the recombinant COVID-19 vaccine Convidecia Air.

The Chinese company is also trying to mass produce and distribute the non-injectable vaccine as a heterologous booster in Indonesia. For the record, CanSino Bio already secured BPOM's approval for intramuscular COVID-19 vaccine Convidecia in Mar 2022.

Market Screener's report on Mar 1 stated that the EUA for Convidecia Air is based on the clinical data showing the use of this inhaled COVID-19 vaccine is effective in people who have received three doses of the vaccine.

The BA.5 neutralizing antibody on day 28 after the vaccine administration was six times bigger than the expected levels.

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

Sign up
Log in
What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.